Raiffeisen Bank International AG
BankPosition in NBIX — Neurocrine Biosciences Inc
CIK 2044885
VIENNA, C4
Position in NBIX
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$2,336,638
+$689,888 QoQ
Shares Held
13,864
+10.9% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#293
of 768 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Derivatives in NBIX
reported options exposure · as of Jun 30, 2026CallValue
$67,416
CallShares
400
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Raiffeisen Bank International AG holds $7,748,668 across 4 Drug Manufacturers - Specialty & Generic names. NBIX ranks #2 (30.2% of the industry book) .
All Filings in NBIX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $67,416 | 400 | Call | Sole | 2026-08-03 | |
| 2026-06-30 | $2,336,638 | 13,864 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $1,646,750 | 12,500 | Shares | Sole | 2026-04-24 | |
| 2026-03-31 | $52,696 | 400 | Call | Sole | 2026-04-24 | |
| 2025-12-31 | $2,638,038 | 18,600 | Shares | Sole | 2026-02-12 | |
| 2025-12-31 | $56,732 | 400 | Call | Sole | 2026-02-12 | |
| 2025-09-30 | $2,536,245 | 18,067 | Shares | Sole | 2025-11-10 | |
| 2025-09-30 | $56,152 | 400 | Call | Sole | 2025-11-10 | |
| 2025-06-30 | $2,112,723 | 16,809 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $1,798,134 | 16,258 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $1,556,100 | 11,400 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||